Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 7/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18578356 | 1.00 | CFD (0.45) | CFDGRIN2BLMNASMN1; SMN2RXFP1 | |
| SCHEMBL29841251 | 0.87 | CFD (0.42) | CFDGRIN2BLMNASMN1; SMN2RXFP1 | |
| SCHEMBL18578623 | 0.87 | CFD (0.42) | CFDGRIN2BLMNASMN1; SMN2RXFP1 | |
| SCHEMBL29545967 | 0.85 | CFD (0.47) | CFDGRIN2BLMNASMN1; SMN2RXFP1 | |
| SCHEMBL18555261 | 0.85 | CFD (0.47) | CFDGRIN2BLMNASMN1; SMN2RXFP1 | |
| SCHEMBL17024799 | 0.81 | CFD (0.41) | CFDLMNASMN1; SMN2CREBBPKMT2A | |
| SCHEMBL29545109 | 0.81 | CFD (0.41) | CFDLMNASMN1; SMN2CREBBPKMT2A | |
| SCHEMBL17037526 | 0.80 | CFD (0.43) | CFDLMNASMN1; SMN2P2RY12CREBBP | |
| SCHEMBL18555130 | 0.78 | CFD (0.60) | CFDGRIN2BLMNASMN1; SMN2P2RY12 | |
| SCHEMBL17024881 | 0.78 | CFD (0.59) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |